Amendments to the Claims

Prior to consideration of the remarks presented herein, Applicants request entry of the following amendments. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (previously presented) A compound of the form:

wherein R is -(CH₂)₂-O-CH₂CH₃.

- 2-9. (canceled)
- 10. (previously presented) A pharmaceutical composition comprising a compound according to claim 1 together with a carrier.
- 11. (currently amended) The composition according to claim 10, wherein said carrier is a pharmaceutical preparation having the form of an ointment or a gel.
- 12. (original) The composition according to claim 10, wherein said carrier is comprised of polymer microparticles.
- 13. (original) The composition according to claim 10, wherein said carrier is a pharmaceutical preparation having the form of a liquid, tablet, or suppository.
- 14. (original) The composition according to claim 10 wherein said carrier is a stent.
- 15. (original) The composition according to claim 14 wherein said stent is formed of metal or polymer.
- 16. (original) The composition according to claim 15 wherein said stent is formed of a biodegradable polymer.

- 17. (original) The composition according to claim 15, wherein said stent is metal and said compound is carried directly on the surface of the stent.
- 18. (original) The composition according to claim 15, where said compound is carried in a polymer layer in contact with said stent.
- 19. (original) The composition according to claim 16, where said compound is carried in a polymer layer in contact with said stent.
 - 20-44. (canceled)
- 45. (currently amended) A method of treating a condition responsive to treatment by rapamycinany of the following conditions:
 - (i) restenosis;
 - (ii) wound healing;
 - (iii) vascular injury;
 - (iv) vascular inflammation; and
 - (v) transplant rejection, comprising administering a compound according to claim 1.
 - 46. (canceled)